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Background: The milk casein-derived biologically active tripeptides, isoleucyl-prolyl-proline (Ile-Pro-Pro) and valyl-prolyl-proline
(Val-Pro-Pro), have documented antihypertensive effect probably related to reduced angiotensin formation. It has been
suggested that these tripeptides may reduce arterial stiffness and improve endothelial function. Our aim was to evaluate
whether the milk-based drink containing Ile-Pro-Pro and Val-Pro-Pro influence arterial stiffness, measured as augmentation index
(AIx), and endothelial function in man.
Methods: In a double-blind parallel group intervention study, 89 hypertensive subjects received daily peptide milk containing a
low dose of tripeptides (5mg/day) for 12 weeks and a high dose (50mg/day) for the following 12 weeks, or a placebo milk drink
to titrate the dose–response effect. Arterial stiffness was assessed by pulse wave analysis at the beginning and end of each
intervention period. Endothelial function was tested by examining pulse wave reflection response to sublingual nitroglycerin and
salbutamol inhalation. Blood pressure was measured by using office and 24-h ambulatory blood pressure measurement.
Results: At the end of the second intervention period, AIx decreased significantly in the peptide group compared with the
placebo group (peptide group  1.53% (95% confidence interval (CI)  2.95 to  0.12), placebo group 1.20% (95% CI 0.09–
2.32), P¼0 013). No change in endothelial function index was observed (peptide group 0.02 (95% CI  0.06 to 0.08), placebo
group 0.04 (95% CI  0.04 to 0.12), P¼0.85). There were no statistically significant differences between the effects of the
peptide and placebo treatment on office and 24-h ambulatory blood pressure.
Conclusions: Long-term treatment with Lactobacillus helveticus-fermented milk containing bioactive peptides reduces arterial
stiffness expressed as AIx in hypertensive subjects.
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Introduction
The milk-derived tripeptides isoleucyl-prolyl-proline (Ile-Pro-
Pro) and valyl-prolyl-proline (Val-Pro-Pro) lower blood
pressure and attenuate the development of hypertension in
spontaneously hypertensive rats after long-term oral intake
(Sipola et al., 2001, 2002a). The mechanisms behind the
antihypertensive effects are partly unknown, but inhibition
of the renin–angiotensin–aldosterone system seems to be
involved (Masuda et al., 1996; Nakamura et al., 1996; Sipola
et al., 2002a). Milk-derived peptides improve vascular
response in vitro probably through stimulation of endothelial
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EJCN EJCNOpennitric oxide (NO) release (Sipola et al., 2002b). It has been
shown in experimental and clinical trials that the tripeptides
Ile-Pro-Pro and Val-Pro-Pro can be absorbed at least partly
from the intestine (Foltz et al., 2007; Jauhiainen et al.,
2007b). Blood pressure-lowering effects of milk products
containing Ile-Pro-Pro and Val-Pro-Pro tripeptides have been
shown in several clinical trials (Seppo et al., 2003; Jauhiainen
et al., 2005) and a meta-analysis of 12 randomized controlled
trials found that the ingestion of tripeptides Ile-Pro-Pro and
Val-Pro-Pro for 4–21 weeks decreases systolic blood pressure
by 4.8mmHg and diastolic blood pressure by 2.2mmHg (Xu
et al., 2008). Another meta-analysis by Pripp (2008) included
intervention studies on both milk tripeptides and other
peptides derived from food, and found a significant effect on
systolic blood pressure of  5.1mmHg and diastolic blood
pressure of  2.4mmHg. By contrast, two recent studies
suggested that milk tripeptides have no significant blood
pressure-lowering effects (Engberink et al., 2008; van der
Zander et al., 2008). The antihypertensive effects of milk-
derived peptides have recently been reviewed (FitzGerald
et al., 2004; Lo ´pez-Fandin ˜o et al., 2006; Hong et al., 2008;
Korhonen 2009).
Impaired endothelial NO synthesis, endothelial dysfunc-
tion, is one of the central elements in the pathogenesis of
atherosclerosis, and is strongly related to hypertension and
dyslipidemia (Panza et al., 1990; Vapaatalo and Mervaala,
2001). An association between endothelial dysfunction and
arterial stiffness has recently been shown (Wilkinson et al.,
2002b). Arterial stiffness is an independent predictor of
cardiovascular morbidity and mortality and has been
associated with hypertension (Boutouyrie et al., 2002).
Earlier studies have suggested that milk tripeptides may
improve arterial stiffness (Jauhiainen et al., 2007a) and
vascular endothelial function in hypertensive subjects
(Hirota et al., 2007).
Our purpose was to examine whether a long-term inter-
vention with a milk product fermented with Lactobacillus
helveticus to produce Ile-Pro-Pro and Val-Pro-Pro has an
impact on arterial stiffness and endothelial function, in
addition to its documented blood pressure-lowering effects.
Materials and methods
Subjects
Eighty-nine subjects participated in this double-blind rando-
mized placebo-controlled parallel group study. The inclusion
criteria were systolic blood pressure between 140 and
155mmHg, diastolic blood pressure between 85 and
99mmHg, and age between 25 and 55 years. Exclusion
criteria were smoking, blood pressure-lowering medication,
secondary hypertension, unstable coronary artery disease,
diabetes mellitus, malignant diseases, alcohol abuse, milk
allergy and pregnancy. A total of 396 mildly to moderately
hypertensive subjects responded to the recruitment in the
Helsinki area. Of the 216 subjects who entered the 4-week
run-in period, 122 did not fulfill the inclusion criteria during
the period when 24-h ambulatory blood pressure recording
was used and were excluded. One subject from the peptide
group and four from the placebo group withdrew from the
study right after the run-in period. A total of 89 subjects (54
males and 35 females) were included in the final analysis.
Design
After the 4-week run-in period, subjects were randomly
allocated to a peptide group that received a L. helveticus-
fermented milk product containing bioactive peptides or to a
placebo group that received a placebo drink with similar
appearance and taste. To test the dose–response effect, two
different peptide concentrations were used. During the first
12 weeks of intervention, the subjects were given daily
200ml of the test product with low doses of the tripeptides
(see below) or placebo. For the following 12 weeks, the
peptide group received two daily 200ml doses of the test
product containing a high concentration (see below) of the
tripeptides or placebo drink. During the run-in period, the
subjects received a daily 200ml dose of a commercial
fermented milk product different to the peptide product or
the placebo product to become familiar with the trial
procedure.
The subjects were asked to maintain their normal lifestyle
and dietary habits, and register their daily use of the
products and any adverse events. Arterial stiffness and
endothelial function testing was performed at the beginning
and at the end of each intervention period by an experienced
clinician (MR). The entire study was conducted in a double-
blinded manner. The study was approved by the Ethics
Committee of the Joint Authority for the Hospital District of
Helsinki and Uusimaa. Written informed consent was
obtained from all participants.
Test products
The peptide test product during the first 12-week interven-
tion period was L. helveticus LBK-16H fermented milk with a
low concentration of peptides (Ile-Pro-Pro 1.2mg/100g and
Val-Pro-Pro 1.3mg/100g) (Valio Ltd., Helsinki, Finland)
measured according to Masuda et al. (1996) During the
following 12-week period, a peptide product with higher
concentrations was given (Ile-Pro-Pro 5.8mg/100g and Val-
Pro-Pro 6.6mg/100g). More detailed data on the product
composition are presented in Table 1.
Arterial stiffness
Arterial stiffness was assessed by pulse wave analysis
(SphygmoCor; AtCor Medical, Sydney, Australia). Blood
pressure was recorded twice in the dominant arm in a lying
position (Omron M4, Omron Matsusaka, Japan). Radial artery
waveforms were recorded with a high-fidelity micromanometer
(SPC-301; Millar Instruments, Houston, TX, USA) from the
Peptide milk reduces arterial stiffness
T Jauhiainen et al
425
European Journal of Clinical Nutritionwrist of the dominant arm. A generalized validated transfer
function was then used to generate a corresponding central
(ascending aortic) waveform (Chen et al., 1997). The aortic
augmentation index (AIx) was calculated as the augmenta-
tion of the aortic systolic blood pressure by the reflected
pulse wave, expressed as a percentage of the aortic pulse
pressure. AIx was adjusted to a heart rate of 75beats/min
calculated by the software that was used in the analyses
(Wilkinson et al., 2000). The time to return of the reflected
wave (Tr) was calculated as the time from the beginning of
the derived aortic systolic pressure waveform to the inflec-
tion point. Tr can be used as a substitute for pulse wave
velocity (a higher pulse wave velocity will result in a shorter
Tr) (London et al., 1992). Subjects were studied after a
minimum 12-h fast in the morning between 0700 to 1000
hours and were asked to refrain from alcohol consumption
and heavy exercise on the day before measurements. Studies
were conducted in a quiet room after a 15-min rest. All
measurements were performed by the same trained physi-
cian (MR).
Endothelial function
Vascular endothelial function was studied using the pulse
wave analysis method (Wilkinson et al., 2002a). This method
examines the effects of an adrenergic b2-agonist salbutamol
and nitroglycerin on the AIx. The reduction of AIx induced
by inhalation of salbutamol reflects activation of the
L-arginine–NO pathway in endothelial cells, whereas the
response to nitroglycerin is an endothelium-independent
measure of vasodilatory capacity. After the baseline record-
ings of AIx, a 500mg tablet of nitroglycerin (Nitro, Orion,
Espoo, Finland) was administered sublingually. AIx was
measured after 3, 5, 10, 15 and 20min. A second baseline
recording of AIx was made 60min later, and immediately
after that two 200mg inhalations of salbutamol (Ventoline
Evohaler, GlaxoSmithKline, London, UK) were given with a
spacer device (Volumatic, GlaxoSmithKline). AIx was mea-
sured 3, 5, 10, 15 and 20min later. The responses to
nitroglycerin and salbutamol were defined as the maximum
change from the respective baseline after drug administra-
tion. An endothelial function index was calculated as the AIx
change induced by salbutamol divided by the AIx change
induced by nitroglycerin, expressed as a percentage.
Twenty-four-h ambulatory blood pressure measurement
At the beginning and end of the intervention periods, blood
pressure was measured with an automatic 24-h blood
pressure recorder (SpaceLab ABP 90207, Redmont, CA,
USA) four times an hour during the daytime and twice an
hour during the night. The measurement was accepted if at
least 80% of the readings were successful; otherwise, the
measurement was repeated.
Blood sampling
Blood samples were drawn at the beginning and at the end of
the two interventions (three times during the study) after an
overnight (12-h) fast. Total cholesterol, high-density
lipoprotein cholesterol and triglycerides were measured
enzymatically, and low-density lipoprotein was calculated
by the Friedewald equation (Friedewald et al., 1972). C-
reactive protein was determined using a turbidimetric
immunoassay (Wako Chemicals, Neuss, Germany) with a
detection limit of 0.1mg/l. At every visit, the subjects were
weighed and body mass index was calculated. No significant
changes were seen during the study periods in these
variables.
Statistical analysis
Analysis was performed according to the intention-to-
treat principle with the last-observation-carried-forward
approach. The results were expressed as the mean or median,
s.d. or interquartile range, and 95 percent confidence
intervals (95% CIs). Statistical comparison of within-groups
in outcome measurements was performed using paired t-test.
The changes in measurements between groups were analyzed
using analysis of covariance with the baseline value as the
covariable.
Table 1 Nutritional composition of the peptide product and the control product
Peptide product Control product
First intervention
period
Second intervention
period
First intervention
period
Second intervention
period
Energy (kJ/100g) 320 320 260 260
Protein (g/100g) 3.5 3.5 3.0 3.0
Fat (g/100g) 0.1 0.1 0.1 0.1
Carbohydrate (g/100g) 15 15 12 12
Calcium (mg/100g) 150 150 84 84
Potassium (mg/100g) 240 240 130 130
Sodium (mg/100g) 35 35 27 27
Ile-Pro-Pro (mg/100g) 1.2 5.8 — —
Val-Pro-Pro (mg/100g) 1.3 6.6 — —
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Results
The clinical characteristics of the subjects at baseline are
presented in Table 2. The subjects reported that they did not
change their dietary intake or physical activity during the
study, and their compliance was excellent. These variables
were followed by recording forms.
No significant changes in the hemodynamic parameters
were observed after 12 weeks of low-dose treatment. The
hemodynamic characteristics at baseline and the changes to
the end of the high-dose treatment (24 weeks) are presented
in Table 3. At week 24, AIx was decreased significantly from
the baseline (P¼0.013) in the peptide group versus the
placebo (Table 3, Figure 1). A subgroup analysis for further
studies, males versus females, was also performed. The
changes between the groups were more pronounced in
males. At 24 weeks, the baseline AIx values had decreased
significantly in males in the peptide group versus the
placebo (peptide  2.30% (95% CI  4.31 to  0.28), placebo
1.74% (95% CI 0.44 to 3.04), P¼0.004). In contrast, the
changes of AIx in women were similar in both groups
(peptide  0.39% (95% CI  2.34 to 1.56), placebo 0.35%
(95% CI  1.77 to 2.48), P¼0.90) (Figure 1). When analyzing
the effects in subjects who fulfilled the International
Diabetes Federation criteria for metabolic syndrome (MS)
(subjects had central obesity, hypertension, and either
reduced high-density lipoprotein cholesterol or raised trigly-
cerides level. Fasting blood glucose values were not measured
and therefore probably only part of the MS subjects was
identified), results showed that the difference between the
genders could be explained by MS (Figure 2). The treatment
effect was highly significant in subjects with MS but not in
subjects who did not fulfill these criteria.
Tr increased from the baseline value in the peptide group
and decreased in the placebo group (Table 3). The difference
between the groups was not significant. However, when
comparing males only, the difference between the groups
was significant (peptide 1.7ms (95% CI  0.44 to 3.9),
placebo  2.1ms (95% CI  4.1 to  0.1), P¼0.022). In
females, no difference from the baseline level was observed
(peptide  1.4ms (95% CI  3.7 to 0.9), placebo  1.6ms (95%
CI  5.2 to 1.9), P¼0.58).
There were no differences between the groups in endothe-
lial function test (endothelial function index) (Table 3). No
differences were seen between males and females (males:
peptide  0.012 (95% CI  0.10 to 0.08), placebo 0.08 (95% CI
 0.03 to 0.20, P¼0.39) (females: peptide 0.06 (95% CI  0.05
to 0.16), placebo  0.02 (95% CI  0.16 to 0.11), P¼0.17).
Table 2 Baseline demographic and clinical data at baseline
Placebo
(N¼44)
Peptide
(N¼45)
Male, n (%) 27 (61) 27 (60)
Age, years, mean (s.d.) 49 (5) 49 (5)
Body mass index, kg/cm
2, mean (s.d.) 28.5 (3.9) 27.6 (3.6)
Waist–hip ratio (s.d.) 0.94 (0.08) 0.90 (0.10)
Blood pressure, mmHg, mean (s.d.)
Systolic 154.6 (13.9) 151.3 (14.8)
Diastolic 94.2 (8.8) 95.2 (12.2)
Mean arterial pressure, mean (s.d.) 113.8 (9.8) 116.8 (10.2)
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Figure 1 Augmentation index (AIx) change to 24 weeks. Bars represent 95% confidence intervals.
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European Journal of Clinical NutritionSystolic and diastolic blood pressures decreased in both
groups from the baseline to 24 weeks (Table 3). Compared
with the placebo group, both systolic and diastolic office
blood pressure values decreased by 2.0mmHg in the peptide
group. Similarly, 24-h ambulatory systolic and diastolic
blood pressure decreased in the peptide group by 3.2 and
1.2mmHg, respectively, compared with the placebo group.
However, the differences between the groups did not reach
statistical significance.
Serum total cholesterol values tended to be lower in the
peptide group (total cholesterol; peptide group  0.21mmol/
l (95% CI  0.43 to 0.01), placebo group 0.034mmol/l (95%
CI  0.16 to 0.23), P¼0.077, low-density lipoprotein choles-
terol; peptide group  0.13mmol/l (95% CI  0.31 to 0.052),
placebo group 0.018mmol/l (95% CI  0.16 to 0.19),
P¼0.17). No significant differences between the groups were
seen in the change of C-reactive protein levels: (peptide
group  0.14 (95% CI  0.77 to 0.49), placebo group 0.026
(95% CI  0.43 to 0.48), P¼0.86).
Discussion
Arterial stiffness is an independent predictor of cardiovas-
cular mortality in hypertensive subjects (Laurent et al., 2001;
Narkiewicz et al., 2007). This study shows that in addition to
its established antihypertensive effects, bioactive peptide-
containing milk drinks improve arterial stiffness measured
by analysis of pulse wave reflection in hypertensive subjects.
This finding is in line with our earlier study, which suggested
that milk tripeptides improve arterial stiffness calculated as
an aortic arterial stiffness index in hypertensive subjects
(Jauhiainen et al., 2007a). In this study, the treatment was
more effective with subjects who fulfilled the International
Diabetes Federation criteria for MS. The result is important,
because a 10% elevation in AIx increases the risk of major
adverse cardiovascular events by 28% in patients with
coronary artery disease and patients with MS are a high-risk
group (Chirinos et al., 2005).
Compared with the placebo group, systolic and diastolic
blood pressure in 24-h readings decreased in the peptide
group by 3.2 and 1.2mmHg, respectively. The difference
between the groups was not statistically significant, but it
may have clinical significance, because it has been estimated
that a decrease in systolic blood pressure by 2mmHg would
reduce the risk for stroke and myocardial infarction by B4%
(Selmer et al., 2000).
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Figure 2 The changes of augmentation index (AIx) to 24 weeks on
subjects with (IDFþ) or without metabolic syndrome (IDF )
according to the International Diabetes Federation (IDF) definition
for metabolic syndrome.
Table 3 Hemodynamic characteristics in the beginning of the intervention and change to 24 weeks
Baseline Change to 24 weeks P-value
a
Placebo mean (s.d.) Peptide mean (s.d.) Placebo mean (95% CI) Peptide mean (95% CI)
Aix, %-units 20.0 (8.4) 24.3 (8.4) 1.20 (0.09 to 2.32)  1.53 ( 2.95 to  0.12) 0.013
AIx GTN, %-units  3.82 (9.26) 0.07 (9.73) 1.20 ( 0.74 to 3.15) 0.33 ( 1.31 to 1.98) 0.79
AIx salbutamol, %-units 7.95 (11.24) 11.71 (10.80) 0.82 ( 1.12 to 2.75)  0.64 ( 2.41 to 1.12) 0.61
Tr, ms 147 (8) 143 (9)  1.9 ( 3.7 to  0.2) 0.5 ( 1.1 to 2.1) 0.13
EFI 0.31 (0.16) 0.32 (0.16) 0.04 ( 0.04 to 0.12) 0.02 ( 0.06 to 0.08) 0.85
Office blood pressure, mmHg
Systolic 151 (15) 155 (14)  2.6 ( 5.7 to 0.6)  4.6 ( 8.4 to  0.8) 0.58
Diastolic 95 (12) 94 (9)  1.7 ( 3.6 to 0.08)  3.7 ( 6.1 to  1.3) 0.14
Twenty-four-h blood pressure, mmHg
Systolic  1.4 ( 4.0 to 1.3)  4 6(  6.9 to  2.3) P¼0.22
Diastolic  1.5 ( 3.3 to 0.3)  2.7 ( 4.2 to  1.2) P¼0.55
Abbreviations: AIx, the aortic augmentation index; CI, confidence interval; EFI, an endothelial function index; Tr, the time to return of the reflected wave.
aAnalysis of covariance with body mass index and baseline measure as covariates.
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European Journal of Clinical NutritionHirota et al. (2007) used plethysmography as an index of
vascular endothelial function and reported that milk
tripeptides improved the vascular endothelial dysfunction.
By contrast, our finding that reduction of pulse wave
reflection induced by b2-adrenergic stimulation was not
significantly improved suggests indirectly that improved
endothelial NO release capacity is not the mechanism by
which L. helveticus-fermented milk exerts its favorable
circulatory effects.
Structural arterial stiffening is a slow process caused by
changes in the extracellular matrix of the arterial walls. As
the present intervention lasted for 24 weeks, it is unlikely
that any major modifications of the elastic properties of the
arterial walls had occurred. A more likely mechanism behind
the finding is reduced functional arterial tone. The fact that
we detected an effect on Tr suggests that the effect is not
confined to increased peripheral resistance in the arterioles,
but rather that medium-sized conduit arteries are also
affected.
Milk protein-derived peptides (a-lactorphin, b-lactorphin
and Ile-Pro-Pro) have beneficial effects on arterial tone in
spontaneously hypertensive rat in vitro (Sipola et al., 2002b;
Ja ¨ka ¨la ¨ et al., 2009). The effect of Ile-Pro-Pro and Val-
Pro-Pro seems to be related to ACE-inhibitory activity
(Ahimastos et al., 2005; Lo ´pez-Fandin ˜o et al. 2006; Hong
et al., 2008).
Another mechanism that must be considered is the fact
that the functional stiffness of the large arteries is affected by
the distensive effect that blood pressure exerts on the arterial
walls (O’Rourke and Gallagher, 1996). Given that both
systolic and diastolic blood pressure diminished in the
intervention group, AIx reduction could to some extent be
explained by lowered blood pressure. In any case, regardless
of the underlying mechanism, reduced arterial stiffness is
beneficial to cardiovascular health by reducing cardiac
afterload and central systolic augmentation.
AIx values could also be influenced by cholesterol and C-
reactive protein levels (Libby et al., 2000; Venugopal et al.,
2002; Verma et al., 2002). In this study, the changes in these
markers were minor and cannot explain the finding. This
study could not show an effect of bioactive tripeptides on
vasodilatation caused by the pharmacological stimulation of
endothelial NO release. However, as basal NO release by the
endothelium is an important determinant of pulse wave
reflection, it can be speculated that the bioactive peptides
improve basal endothelial NO release, although the maximal
capacity of NO release is unaffected.
In addition to these suggested mechanisms, the positive
effect on arterial stiffness could also be influenced by the
mineral composition of peptide milk. Calcium has been
shown to enhance vasorelaxation in experimental trials
(Ma ¨kynen et al., 1996; Jones et al., 1997). Potassium and
magnesium also have beneficial effects on vascular function
(Mervaala et al., 1994; Ma ¨kynen et al., 1995; Tolvanen et al.,
1998). On the other hand, the electrolyte concentrations did
not differ markedly between the test and placebo drinks.
When evaluating the strengths and limitations of this
study, the authors see many strengths. The number of
recruited subjects was quite marked, about 400. Of them,
more than half were selected for the 4-week run-in period,
during which again about half were excluded on the basis of
strict criteria of hypertension in an ambulatory 24-h blood
pressure registration. Thus, the final material (89 subjects)
was quite homogeneous and regarded as moderately hyper-
tensive. The subjects were motivated, seemed to follow the
instructions carefully and not to change their living habits
(nutrition intake, physical activity), which were recorded.
Daily intake of test drinks was also recorded and the
compliance was excellent. Furthermore, dose titrating,
which has not been used in many previous studies, was
one of our advantages. The authors have long experience
and expertise in carrying out clinical trials generally and
especially in the cardiovascular field. The long treatment
periods (3 months each) guaranteed the stabilization of the
treatment effects.
A limitation to the study can be regarded as the lack of
power calculations because of the absence of previous data.
Also, the lack of fasting glucose analyses was a weakness and
the number of subjects in the subgroup analysis was
therefore very small. More detailed cardiovascular reactivity
tests might have given some more information. Two more
clinical studies using more sophisticated methods of clinical
physiology are in progress.
In conclusion, we found that the long-term intake of L.
helveticus-fermented milk containing Ile-Pro-Pro and Val-Pro-
Pro tripeptides reduces arterial stiffness expressed as AIx in
hypertensive subjects.
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